EE506 RNA Interference Therapies for hATTR Amyloidosis With Polyneuropathy: Differential Healthcare Resource Use and Direct and Indirect Cost Consequences Associated With Vutrisiran Versus Patisiran
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.771
https://www.valueinhealthjournal.com/article/S1098-3015(23)03901-3/fulltext
Section Title :
Section Order :
10259
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03901-3&doi=10.1016/j.jval.2023.09.771